



HU000029434T2

(19) **HU**(11) Lajstromszám: **E 029 434**(13) **T2****MAGYARORSZÁG**  
Szellemi Tulajdon Nemzeti Hivatala**EURÓPAI SZABADALOM**  
**SZÖVEGÉNEK FORDÍTÁSA**

- (21) Magyar ügyszám: **E 10 717084**
- (22) A bejelentés napja: **2010. 04. 13.**
- (96) Az európai bejelentés bejelentési száma:  
**EP 20100717084**
- (97) Az európai bejelentés közzétételi adatai:  
**EP 2419108 A1**                      **2010. 10. 21.**
- (97) Az európai szabadalom megadásának meghirdetési adatai:  
**EP 2419108 B1**                      **2016. 08. 17.**
- (51) Int. Cl.: **A61K 31/56**                      (2006.01)  
**A61K 9/06**                      (2006.01)  
**A61K 31/57**                      (2006.01)  
**A61K 9/20**                      (2006.01)
- (86) A nemzetközi (PCT) bejelentési szám:  
**PCT/EP 10/054812**
- (87) A nemzetközi közzétételi szám:  
**WO 10119029**

(30) Elsőbbségi adatok: <b>169149 P</b> <b>2009. 04. 14.</b> <b>US</b>	(73) Jogosult(ak): <b>Laboratoire HRA Pharma, 75003 Paris (FR)</b> <b>The United States of America, as represented</b> <b>by The Secretary, Department of Health and</b> <b>Human Services, Bethesda, MD 20892-7660</b> <b>(US)</b>
(72) Feltaláló(k): <b>ULMANN, André, F-75005 Paris (FR)</b> <b>GAINER, Erin, F-75019 Paris (FR)</b> <b>BLITHE, Diana, Silver Spring, MD 20906 (US)</b> <b>NIEMAN, Lynette, Bethesda, MD 20817 (US)</b> <b>MATHE, Henri Camille, 75018 Paris (FR)</b>	(74) Képvisező: <b>SBGK Szabadalmi Ügyvivői Iroda, Budapest</b>

(54) **Eljárás sürgősségi fogamzásgátlásra**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(11) **EP 2 419 108 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention  
of the grant of the patent:  
**17.08.2016 Bulletin 2016/33**

(51) Int Cl.:  
**A61K 31/56** <sup>(2006.01)</sup> **A61K 31/57** <sup>(2006.01)</sup>  
**A61K 9/20** <sup>(2006.01)</sup> **A61K 9/06** <sup>(2006.01)</sup>

(21) Application number: **10717084.7**

(86) International application number:  
**PCT/EP2010/054812**

(22) Date of filing: **13.04.2010**

(87) International publication number:  
**WO 2010/119029 (21.10.2010 Gazette 2010/42)**

(54) **METHOD FOR ON-DEMAND CONTRACEPTION**

VERFAHREN ZUR BEDARFSWEISEN KONTRAZEPTION

METHODE DE CONTRACEPTION À LA DEMANDE

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL  
PT RO SE SI SK SM TR**  
Designated Extension States:  
**AL BA ME RS**

(30) Priority: **14.04.2009 US 169149 P**

(43) Date of publication of application:  
**22.02.2012 Bulletin 2012/08**

(73) Proprietors:  
• **Laboratoire HRA Pharma**  
**75003 Paris (FR)**  
• **The United States of America, as represented by**  
**The Secretary, Department of Health and Human**  
**Services**  
**Bethesda, MD 20892-7660 (US)**

(72) Inventors:  
• **ULMANN, André**  
**F-75005 Paris (FR)**

• **GAINER, Erin**  
**F-75019 Paris (FR)**  
• **BLITHE, Diana**  
**Silver Spring, MD 20906 (US)**  
• **NIEMAN, Lynette**  
**Bethesda, MD 20817 (US)**  
• **MATHE, Henri Camille**  
**75018 Paris (FR)**

(74) Representative: **Chajmowicz, Marion et al**  
**Becker & Associés**  
**25, rue Louis Le Grand**  
**75002 Paris (FR)**

(56) References cited:  
**WO-A1-00/09136 WO-A2-2008/079245**  
**WO-A2-2008/122439 WO-A2-2010/066749**

• **ORIHUELA PEDRO A: "Ulipristal, a progesterone  
receptor antagonist as a contraceptive and for the  
treatment of uterine fibroids" CURRENT OPINION  
IN INVESTIGATIONAL DRUGS, PHARMAPRESS,  
US, vol. 8, no. 10, 1 October 2007 (2007-10-01),  
pages 859-866, XP009115744 ISSN: 1472-4472**

**EP 2 419 108 B1**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

[0001] The present invention relates to methods for on-demand contraception in a woman, especially women who do not have a regular sexual activity.

5

**Technical background of the invention:**

[0002] Hormonal contraception is considered the most reliable method of reversible contraception today. It requires the continuous taking of pills, generally daily, regardless of the frequency of intercourses. For women with infrequent sexual intercourse, however, preparations that are dependent on coitus and thus can be taken less often, with reduced exposure to the effective ingredients, would be more advantageous. Although recognized for a long time (Canzler et al, Zbl. Gynäkol, 1984, 106:1182-1191), the need for such on-demand contraception remains unmet (Aitken et al, Contraception, 2008, 78:S28-S35).

10

Women are actually creating such methods themselves out of existing products. In Ghana, a study conducted in 2003 reported that women were using norethindrone tablets, marketed for treatment of various gynecologic problems, as an "on demand" oral contraceptive. More recently, anecdotal reports and data collected by colleagues at Family Health International indicate that women in other parts of Africa and elsewhere are deliberately using emergency contraceptive pills in this manner.

15

Although oral methods do not provide protection against sexually transmitted infections, studies conducted several decades ago reported that various doses of levonorgestrel used as a regular postcoital contraceptive may provide protection with an efficacy comparable to the overall efficacy of condoms and other barrier methods in typical use (United Nations Development Programme/ United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Post-Ovulatory Methods of Fertility Regulation. Efficacy and side effects of immediate postcoital levonorgestrel used repeatedly for contraception. Contraception 2000;61:303-8). It was further proposed to evaluate whether a single vaginal administration of levonorgestrel gel prior to intercourse would interfere with the ovulatory process. (Brache et al, Contraception, 2007; 76:111-116).

20

25

[0003] Other progestative agents have been used as post-coital emergency contraception. Emergency contraception (EC) refers to back-up methods for contraceptive emergencies which women can use within the first few days after unprotected intercourse to prevent an unwanted pregnancy. For instance the preclinical studies and the first clinical trials with ulipristal acetate, developed by HRA Pharma for emergency contraception, have proved that a single dose of 50 mg of ulipristal acetate is safe and efficacious when administered to women seeking emergency contraception within 72 hours after unprotected intercourse (Creinin et al, 2006, Obstetrics and Gynecology, 108(5):1089-1097).

30

35

**Summary of the invention:**

[0004] The invention provides a method for contraception, which method comprises on-demand administering a progestogen agent or a progesterone receptor modulator in a woman, within 72 hours before an intercourse, which administration can be repeated at least once a week.

40

[0005] The invention also provides a method for contraception, comprising on-demand administering a progestogen agent or a progesterone receptor modulator thereof in a woman, within 120 hours after an intercourse, preferably at least twice a month.

[0006] In a preferred embodiment, the invention provides a method for contraception, which method comprises on-demand administering a progestogen agent or a progesterone receptor modulator thereof, such as 17 $\alpha$ -acetoxy-11b-[4-N, N-dimethylamino-phenyl]-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) or a metabolite thereof, in a woman, within 72 hours before an intercourse, which administration can be repeated at least once a week.

45

[0007] The invention also provides a method for contraception, comprising on-demand administering a progestogen agent or a progesterone receptor modulator thereof, such as 17 $\alpha$ -acetoxy-11b-[4-N, N-dimethylamino-phenyl]-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) or a metabolite thereof, in a woman, within 120 hours after an intercourse, preferably at least twice a month.

50

**Detailed description of the invention:**

[0008] The inventors have studied whether ulipristal acetate could be used not only as an emergency contraceptive, but also as a regular hormonal contraceptive.

55

For that purpose, health cycling volunteers received 3 months of continuous daily administration of ulipristal acetate (2.5, 5 or 10 mg) or placebo.

Assessment of ovarian hormones, follicular development, endometrial histology, and menstrual bleeding patterns was

carried out during the third month of treatment.

One patient (treated with 10 mg of ulipristal acetate/day) missed 2 days of drug in her third treatment cycle (days 1 and 2) and yet had no sign of luteal activity or ovulation. This made the inventors think that ulipristal acetate could be used as a contraceptive which could be taken on-demand, rather than everyday as any hormonal contraceptive pill.

5 On this basis, the invention provides a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17 $\alpha$ -acetoxy-11 $\beta$ -[4-N, N-dimethylamino-phenyl]-19-norpregna- 4, 9-diene-3, 20-dione (ulipristal acetate) or a metabolite thereof, in a woman, within 72 hours *before* an intercourse, and/or within 120 hours *after* an intercourse.

10 The invention further provides a method for contraception, which method comprises discontinuously administering a progestogen agent or progesterone receptor modulator, such as ulipristal acetate or a metabolite thereof, in a woman. More particularly the progestogen agent or progesterone receptor modulator, such as ulipristal acetate or a metabolite thereof, may be administered less than once a day during the menstrual cycle. Preferably it is administered at least once a week during the menstrual cycle.

15 **[0009]** More generally, the inventors propose to use progestogen agents or progesterone receptor modulators for on-demand contraception.

#### Progestogen agents:

20 **[0010]** The progestogen agents, also designated progestins, may be any progestationally active compound.

**[0011]** The progestogen agents may be selected from progesterone and its derivatives such as, for example, 17-hydroxy progesterone esters, 19-nor-17-hydroxy progesterone esters, 17 $\alpha$ -ethinyltestosterone and derivatives thereof, 17 $\alpha$ -ethinyl-19-nor-testosterone and derivatives thereof, norethindrone, norethindrone acetate, ethynodiol diacetate, dydrogesterone, medroxy-progesterone acetate, norethynodrel, allylestrenol, lynoestrenol, fuingestanol acetate, medrogestone, norgestrienone, dimethiderome, ethisterone, cyproterone acetate, levonorgestrel, DL-norgestrel, D-17 $\alpha$ -acetoxy-13 $\beta$ -ethyl-17 $\alpha$ -ethinyl-gon-4-en-3-one oxime, gestodene, desogestrel, norgestimate, nestorone and drosiprenone.

25 **[0012]** In a preferred embodiment, it is to be understood that the progestogen agent is not combined with any other hormonal contraceptive agent, such as an estrogen. In that case, the contraceptive is often referred to as a "progestin-only" contraceptive.

30


#### Progesterone receptor modulators:

**[0013]** Progesterone receptor modulators for use in the present invention may be selected from e.g., ulipristal acetate, mifepristone or CDB-4124 or active metabolites thereof.

35 **[0014]** The preferred progesterone receptor modulator is ulipristal acetate.

Ulipristal acetate, formerly known as CDB-2914, is 17 $\alpha$ -acetoxy-11 $\beta$ -[4-N, N-dimethylamino-phenyl]-19-norpregna- 4, 9-diene-3, 20-dione, represented by formula I:

40



45

I

50


**[0015]** It is a well-known steroid, more specifically a 19-norprogesterone, which possesses antiprogesterone and antigluocorticoidal activity. This compound, and methods for its preparation, are described in U. S. Patent Nos. 4,954,490, 5,073,548, and 5,929,262, and international patent applications WO2004/065405 and WO2004/078709. Properties of this compound are further described in Blithe et al, 2003, Steroids, 68:1013-1017 and Gainer and Ulmann, 2003, Steroids, 68:1005-1011.

Metabolites of CDB-2914, include those described in Attardi et al, Journal of Steroid Biochemistry & Molecular Biology,

## EP 2 419 108 B1

2004, 88: 277-288, e.g. monodemethylated CDB-2914 (CDB-3877) ; didemethylated CDB-2914 (CDB-3963) ; 17 $\alpha$ -hydroxy CDB-2914 (CDB-3236); aromatic A-ring derivative of CDB-2914 (CDB-4183).


5



10

monodemethylated CDB-2914


15



20

didemethylated CDB-2914


25



30

17 $\alpha$ -hydroxy CDB-2914

35



40

aromatic A-ring CDB-2914

### 45 On-demand:

**[0016]** The subject or patient can be any human female. The invention provides an "on-demand contraception", which means that the woman may take a progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof at any time when needed, i.e. when an intercourse is expected, or has recently occurred. Preferably, the woman does not use any other hormonal contraceptive medication. In another preferred embodiment, the subject does not use any protection (condom, uterine device, spermicide, etc).

The woman may want to use the progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof, as a regular contraceptive when her sexual activity becomes more regular. Preferably the administration is then repeated at least once a week, preferably once a week or four times during a menstrual cycle, or twice during a menstrual cycle, or three times during a menstrual cycle. The term « repeated » means that one dosage unit of the progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof, is administered twice or more, during the menstrual cycle.

**[0017]** In any event, the woman always uses the progestogen agent or progesterone receptor modulator, e.g. ulipristal

acetate or a metabolite thereof on-demand, and not on a daily basis, and preferably not more than ten days in a row, preferably not more than nine, eight, seven, six, five, four, three or two days in a row. Preferably the progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof is not administered more than four days, three or two days in a row.

5

Routes of administration:

**[0018]** The progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof may be administered by any convenient route, including oral, buccal, sublingual, parenteral, transdermal, vaginal, rectal, etc.

10 **[0019]** For a brief review of present methods for drug delivery, see, Langer, Science 249:1527-1533 (1990), which is incorporated herein by reference. Methods for preparing administrable compounds are known or are apparent to those skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 17th Ed., Mack Publishing Company, Easton, Pa. (1985), which is incorporated herein by reference, and which is hereinafter referred to as "Remington."

15 **[0020]** Unit dosages of immediate-release formulations are preferred.

**[0021]** For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose. For oral administration, a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed.

20 **[0022]** Oral solid dosage forms are preferentially compressed tablets or capsules. Compressed tablets may contain diluents to increase the bulk of the progestogen agent or progesterone receptor modulator so that production of a compressed tablet of practical size is possible. Binders, which are agents which impart cohesive qualities to powdered materials may be also necessary. Povidone, starch, gelatin, sugars such as lactose or dextrose, and natural and synthetic gums may be used. Disintegrants are generally necessary in the tablets to facilitate break-up of the tablet. Disintegrants include starches, clays, celluloses, algin, gums and crosslinked polymers. Lastly small amounts of materials known as lubricants and glidants are included in the tablets to prevent adhesion of the tablet material to surfaces in the manufacturing process and to improve the flow characteristics of the powder material during manufacture. Colloidal silicon dioxide is most commonly used as a glidant and compounds such as talc, magnesium stearate or stearic acids are most commonly used as lubricants. Procedures for the production and manufacture of compressed tablets are well known by those skilled in the art (See Remington).

30 **[0023]** Capsules are solid dosage forms using preferentially either a hard or soft gelatin shell as a container for the mixture of the progestogen agent or progesterone receptor modulator and inert ingredients. Procedures for production and manufacture of hard gelatin and soft elastic capsules are well known in the art (See Remington).

**[0024]** Buccal or sublingual forms or devices are also useful.

35 **[0025]** For parenteral administration, fluid unit dosage forms are prepared utilizing the compounds and a sterile vehicle, water being preferred. The progestogen agent or progesterone receptor modulator, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filtered sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection is supplied to reconstitute the liquid prior to use. Parenteral suspensions can be prepared in substantially the same manner except that the compounds are suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the progestogen agent or progesterone receptor modulator.

45 **[0026]** Additionally, a suppository or a pessary can be employed to deliver the progestogen agent or progesterone receptor modulator. The active compound can be incorporated into any of the known suppository bases by methods known in the art. Examples of such bases include cocoa butter, polyethylene glycols (carbowaxes), polyethylene sorbitan monostearate, and mixtures of these with other compatible materials to modify the melting point or dissolution rate. These suppositories can weigh from about 1 to 2.5 gm.

50 **[0027]** Transdermal delivery systems comprising a penetration enhancer and an occlusive backing are of use to deliver the progestogen agent or progesterone receptor modulator. Examples of penetration enhancers include dimethyl sulfoxide, dimethyl acetamide and dimethylformamide. Transcutaneous gels may be advantageous too. Examples of such gels are described e.g. in U.S. patent 5,904,931.

55 **[0028]** The progestogen agent or progesterone receptor modulator may be administered by vaginal route, for instance in the form of a gel or a vaginal device.

In another embodiment, the method of the invention comprises on-demand inserting a vaginal device, such as a vaginal

ring that releases the progestogen agent or progesterone receptor modulator, in a woman, within 24 hours before or after an intercourse.

The vaginal ring usually comprises a synthetic polymer, which can be a silicone elastomer or a non-silicone resin. In a particular embodiment the ring comprises a polymer core, surrounded by an outer polymer layer comprising the progestogen agent or progesterone receptor modulator. In a particular embodiment, the ring is as described in international patent application WO2006/010097.

Preferably, the vaginal ring is removed within 12 hours after the intercourse. Most preferably, the vaginal ring is maintained in place for a minimum of 6 to 12 hours.

**[0029]** The oral route is preferred. Other routes of administration can be suitable in comparison with oral routes using blood levels to provide clinical success.

Dosages

**[0030]** The unit dosage of the progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof, may be between 10 and 40mg, preferably 20mg or 30mg. Preferably the unit dosage of progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof is to be administered orally.

Regimen:

**[0031]** In a first embodiment of the invention, the progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof, can be administered within 72 hours *before* an intercourse, preferably within 48h before the intercourse, more preferably within 24h before the intercourse, still more preferably within 12h before the intercourse.

**[0032]** In a second embodiment of the invention, the progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof can be administered within 120 hours *after* an intercourse, preferably within 72h after the intercourse, more preferably within 48h after the intercourse, still more preferably within 24h after the intercourse, even more preferably within 12h after the intercourse.

**[0033]** In a preferred embodiment, the administration is repeated at least twice a month, preferably three times a month or once a week.

**[0034]** For optimal efficiency, the two embodiments may be combined, *i.e.* a progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof, can be administered within 72 hours *before* an intercourse, and the same woman can also take a progestogen agent or progesterone receptor modulator, e.g. ulipristal acetate or a metabolite thereof, within 120 hours *after* the intercourse.

**[0035]** The following example is provided by way of illustration only and not by way of limitation.

**Example : Multiple intakes of ulipristal acetate within a menstrual cycle.**

**[0036]** Several women received ulipristal acetate (30 mg) after a declared intercourse, twice during a menstrual cycle.

No pregnancy was observed.

Patient	1 <sup>st</sup> intake	2 <sup>nd</sup> intake
Woman 1	intercourse: Dec 11,2007 06:00*	intercourse: Dec 14, 2007 21:00
	Ulipristal acetate intake : Dec 13, 2007 11:25	Dec 14, 2007 14:37
Woman 2	intercourse: Dec 12, 2007 05:00	intercourse: Dec 15, 2007 23:00
	Ulipristal acetate intake : Dec 14, 2007	Ulipristal acetate intake : Dec 18, 2007 10:45

EP 2 419 108 B1

(continued)

Patient	1 <sup>st</sup> intake	2 <sup>nd</sup> intake
	11:05	
5 Woman 3	intercourse: Dec 15, 2007 06:00  Ulipristal acetate intake : Dec 17, 2007 11:40	intercourse: Dec 15, 2007 22:00  Ulipristal acetate intake : Dec 18, 2007 11:15
10 Woman 4	intercourse: Dec 14, 2007 01:00  Ulipristal acetate intake : Dec 17, 2007 12:20	intercourse: Dec 07, 2007 20:00  Ulipristal acetate intake : Dec 12, 2007 10:58
15 Woman 5	intercourse: Nov 5, 2007 06:00  Ulipristal acetate intake : Nov 8, 2007 15:30	intercourse: Nov 2, 2007 08:00  Ulipristal acetate intake : Nov 5, 2007 15:00
20 25 30	<i>* time are expressed in 24 hours format</i>	

**Claims**

1. A method for contraception comprising orally administering a woman with an immediate-release form comprising ulipristal acetate or a metabolite thereof at an amount of 30 mg, within 120 hours after an intercourse.
2. The method of claim 1 wherein the solid form is administered within 72 h after the intercourse.
3. The method of claims 1 or 2, wherein the immediate-release form is a tablet.
4. The method of claim 3 wherein the tablet comprises a diluent, a binder, and a disintegrant.
5. The method of any one of claims 1-4 wherein the metabolite is selected from the group consisting of CDB-3877, CDB-3963, CDB-3236 and CDB-4183.
6. The method of any one of claims 1-5 wherein the administration is repeated at least twice in a month.

**Patentansprüche**

1. Ein Verfahren zur Empfängnisverhütung, wobei das Verfahren das orale Verabreichen von Ulipristalacetat oder eines Metaboliten davon an eine Frau in einer Darreichungsform mit sofortiger Freisetzung, in einer Menge von 30 mg und innerhalb von 120 Stunden nach einem Geschlechtsverkehr umfasst.

## EP 2 419 108 B1

2. Das Verfahren nach Anspruch 1, wobei die feste Darreichungsform innerhalb von 72 Stunden nach dem Geschlechtsverkehr verabreicht wird.
3. Das Verfahren nach Anspruch 1 oder 2, wobei die Darreichungsform mit sofortiger Freisetzung eine Tablette ist.
4. Das Verfahren nach Anspruch 3, wobei die Tablette ein Verdünnungsmittel, ein Bindemittel, und ein Zerfallsmittel umfasst.
5. Das Verfahren nach einem der Ansprüche 1-4, wobei der Metabolit aus der Gruppe bestehend aus CDB-3877, CDB-3963, CDB-3236 und CDB-4183 ausgewählt ist.
6. Das Verfahren nach einem der Ansprüche 1-5, wobei die Verabreichung mindestens zweimal in einem Monat wiederholt wird.

### Revendications

1. Méthode de contraception comprenant l'administration orale à une femme d'une forme à libération immédiate comprenant de l'ulipristal acétate ou un métabolite de celui-ci en une quantité de 30 mg, dans les 120 h après un rapport sexuel.
2. Méthode selon la revendication 1 dans laquelle la forme solide est administrée dans les 72 heures après le rapport sexuel.
3. Méthode selon la revendication 1 ou 2, dans laquelle la forme à libération immédiate est un comprimé
4. Méthode selon la revendication 3, dans laquelle le comprimé comprend un diluant, un agent liant, et un désintégrant.
5. Méthode selon l'une quelconque des revendications 1-4 dans laquelle le métabolite est choisi dans le groupe constitué par CDB-3877, CDB-3963, CDB-3236 et CDB-4183.
6. Méthode selon l'une quelconque des revendications 1-5 dans laquelle l'administration est répétée au moins deux fois dans le mois.

REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

Patent documents cited in the description

- US 4954490 A [0015]
- US 5073548 A [0015]
- US 5929262 A [0015]
- WO 2004065405 A [0015]
- WO 2004078709 A [0015]
- US 5904931 A [0027]
- WO 2006010097 A [0028]

Non-patent literature cited in the description

- **CANZLER et al.** *Zbl. Gynäkol*, 1984, vol. 106, 1182-1191 [0002]
- **AITKEN et al.** *Contraception*, 2008, vol. 78, S28-S35 [0002]
- Efficacy and side effects of immediate postcoital levonorgestrel used repeatedly for contraception. *Contraception*, 2000, vol. 61, 303-8 [0002]
- **BRACHE et al.** *Contraception*, 2007, vol. 76, 111-116 [0002]
- **CREININ et al.** *Obstetrics and Gynecology*, 2006, vol. 108 (5), 1089-1097 [0003]
- **BLITHE et al.** *Steroids*, 2003, vol. 68, 1013-1017 [0015]
- **GAINER ; ULMANN.** *Steroids*, 2003, vol. 68, 1005-1011 [0015]
- **ATTARDI et al.** *Journal of Steroid Biochemistry & Molecular Biology*, 2004, vol. 88, 277-288 [0015]
- **LANGER.** *Science*, 1990, vol. 249, 1527-1533 [0019]
- Remington's Pharmaceutical Science. Mack Publishing Company, 1985 [0019]



SZTNH-100044033

715629/GM  
EP 2 419 108 B1

### Szabadalmi igénypontok

1. Eljárás fogamzásgátlásra, amely magában foglalja uliprisztál-acetát vagy annak egy metabolitja azonnali kibocsátású kiszerezésének orális adagolását egy nőnek 30 mg mennyiségben közösülés után 120 órán belül.
2. Az 1. igénypont szerinti eljárás, ahol a szilárd kiszerezést közösülés után 72 órán belül adagoljuk.
3. Az 1. vagy 2. igénypont szerinti eljárás, ahol az azonnali kibocsátású kiszerezés tabletta.
4. A 3. igénypont szerinti eljárás, ahol a tabletta hígítót, kötőanyagot és szétesés elősegítőt tartalmaz.
5. Az 1-4. igénypontok bármelyike szerinti eljárás, ahol a metabolitot az alábbiakból álló csoportból választjuk: CDB-3877, CDB-3963, CDB-3236 és CDB-4183.
6. Az 1-5. igénypontok bármelyike szerinti eljárás, ahol az adagolást megismételjük legalább kétszer egy hónapban.

A meghatalmazott:

Dr. Gál Melinda  
*Gál Melinda*  
SOGK Szabadalmi Ügyvivői Iroda  
H-1062 Budapest, Andrássy út 113.  
Telefon: 461-1000 Fax: 461-1009  
Email: gal@stgk.hu